Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1383-1388

  Groves, Morris D ^a   Puduvalli, Vinay K ^a   Hess, Kenneth R ^a   Jaeckle, Kurt A ^a   Peterson, Pamela ^a   Yung, W K Alfred ^a   Levin, Victor A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; TEMOZOLOMIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GLIOBLASTOMA; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 0036499078     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1383     Document Type: Article

References (31)

1. Neoplasms of the central nervous system
2. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
3. A comparison of treatment results for recurrent malignant gliomas
4. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity
5. Anti-tumour imidazotetrazines, part XXI: Mitozolomide and temozolomide-Probes for the major groove of DNA
6. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-D]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine
7. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
8. Matrix metalloproteinases: Biologic activity and clinical implications
9. Cancer cell invasion and metastasis
10. Matrix metalloproteinase inhibition: A review of anti-tumour activity
11. Expression of matrix metalloproteinases and their inhibitors in human brain tumors
12. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo
13. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
14. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro
15. Marimastat: The clinical development of a matrix metalloproteinase inhibitor
16. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma
17. Matrix metalloproteinase inhibitors: Present achievements and future prospects
18. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer
19. Phase IB study of concurrent administration of marimastat and gemcitabine in nonresectable pancreatic cancer
20. Marimastat (BB2516): Current status of development
21. A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer
22. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
23. "... Those left behind": Biology and oncology of invasive glioma cells
24. Dichotomy of astrocytoma migration and proliferation
25. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
26. Activity of temozolomide in the treatment of central nervous system tumor xenografts
27. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft
28. Adenovirally-mediated transfer of E2F-potentiates chemosensitivity of human glioma cells to temozolomide and BCNU
29. Extracellular matrix degradation
30. Matrix metalloproteinases in angiogensis: A moving target for therapeutic intervention